X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs PIRAMAL ENTERPRISES - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD PIRAMAL ENTERPRISES BIOCON LTD/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 49.7 8.3 595.4% View Chart
P/BV x 7.2 1.5 484.6% View Chart
Dividend Yield % 0.2 1.1 14.7%  

Financials

 BIOCON LTD   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
PIRAMAL ENTERPRISES
Mar-18
BIOCON LTD/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,1883,083 38.5%   
Low Rs3051,902 16.0%   
Sales per share (Unadj.) Rs68.7589.7 11.7%  
Earnings per share (Unadj.) Rs7.6284.0 2.7%  
Cash flow per share (Unadj.) Rs14.0310.5 4.5%  
Dividends per share (Unadj.) Rs1.0025.00 4.0%  
Dividend yield (eoy) %0.11.0 13.4%  
Book value per share (Unadj.) Rs86.31,467.0 5.9%  
Shares outstanding (eoy) m600.00180.27 332.8%   
Bonus/Rights/Conversions ISIS-  
Price / Sales ratio x10.94.2 257.0%   
Avg P/E ratio x98.98.8 1,126.5%  
P/CF ratio (eoy) x53.48.0 665.7%  
Price / Book Value ratio x8.61.7 508.8%  
Dividend payout %13.28.8 150.4%   
Avg Mkt Cap Rs m447,900449,332 99.7%   
No. of employees `0006.16.8 89.9%   
Total wages/salary Rs m9,31119,881 46.8%   
Avg. sales/employee Rs Th6,705.815,535.6 43.2%   
Avg. wages/employee Rs Th1,514.22,905.4 52.1%   
Avg. net profit/employee Rs Th736.97,482.5 9.8%   
INCOME DATA
Net Sales Rs m41,234106,310 38.8%  
Other income Rs m2,0622,595 79.5%   
Total revenues Rs m43,296108,906 39.8%   
Gross profit Rs m8,29151,599 16.1%  
Depreciation Rs m3,8514,773 80.7%   
Interest Rs m61529,783 2.1%   
Profit before tax Rs m5,88719,638 30.0%   
Minority Interest Rs m2132,801 7.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,569-28,764 -5.5%   
Profit after tax Rs m4,53151,203 8.8%  
Gross profit margin %20.148.5 41.4%  
Effective tax rate %26.7-146.5 -18.2%   
Net profit margin %11.048.2 22.8%  
BALANCE SHEET DATA
Current assets Rs m41,486118,154 35.1%   
Current liabilities Rs m21,413462,260 4.6%   
Net working cap to sales %48.7-323.7 -15.0%  
Current ratio x1.90.3 758.0%  
Inventory Days Days6427 240.7%  
Debtors Days Days9447 202.4%  
Net fixed assets Rs m50,661113,727 44.5%   
Share capital Rs m3,000361 832.2%   
"Free" reserves Rs m48,808264,093 18.5%   
Net worth Rs m51,808264,454 19.6%   
Long term debt Rs m17,898242,206 7.4%   
Total assets Rs m99,897726,834 13.7%  
Interest coverage x10.61.7 637.1%   
Debt to equity ratio x0.30.9 37.7%  
Sales to assets ratio x0.40.1 282.2%   
Return on assets %5.211.1 46.2%  
Return on equity %8.719.4 45.2%  
Return on capital %9.610.3 93.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05815,110 79.8%   
Fx outflow Rs m7,3484,298 171.0%   
Net fx Rs m4,71010,813 43.6%   
CASH FLOW
From Operations Rs m6,621-159,666 -4.1%  
From Investments Rs m-6,840-17,677 38.7%  
From Financial Activity Rs m-2,397186,503 -1.3%  
Net Cashflow Rs m-2,6129,364 -27.9%  

Share Holding

Indian Promoters % 40.4 52.9 76.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 4.0 210.0%  
FIIs % 10.7 26.6 40.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 16.5 120.6%  
Shareholders   109,995 93,274 117.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Nov 14, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS